Clovis Oncology, Inc.
CLVSDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
rucaparib
Metastatic Breast Cancer
CO-1.01
Metastatic Pancreatic Adenocarcinoma
Copanlisib
Metastatic Castration-resistant Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rucaparib | Phase 3 | Metastatic Breast Cancer | - | - |
CO-1.01 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Copanlisib | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Clovis Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Clovis Oncology, Inc.'s (CLVS) pipeline across Phase 3, Phase 2. Its lead program is rucaparib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Clovis Oncology, Inc.'s next FDA catalyst?→
Clovis Oncology, Inc.'s (CLVS) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLVS biotech catalysts?→
Add CLVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Clovis Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.